Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 415

1.

Utility of multiphasic multidetector computed tomography in discriminating between clear cell renal cell carcinomas with high and low carbonic anhydrase-IX expression.

Young JR, Coy H, Kim HJ, Douek M, Sisk A, Belldegrun A, Pantuck AJ, Raman SS.

Abdom Radiol (NY). 2018 Mar 8. doi: 10.1007/s00261-018-1546-8. [Epub ahead of print]

PMID:
29520426
2.

Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma.

Lenis AT, Salmasi AH, Donin NM, Faiena I, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun AS, Pantuck AJ, Chamie K.

Urol Oncol. 2018 Feb;36(2):78.e21-78.e28. doi: 10.1016/j.urolonc.2017.09.030. Epub 2017 Nov 8.

PMID:
29128421
3.

Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection.

Faiena I, Salmasi A, Lenis AT, Donin NM, Johnson DC, Bachour K, Drakaki A, Belldegrun AS, Pantuck AJ, Chamie K.

Urol Oncol. 2018 Feb;36(2):79.e19-79.e26. doi: 10.1016/j.urolonc.2017.10.009. Epub 2017 Nov 2.

PMID:
29103965
4.

Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma.

Lenis AT, Donin NM, Faiena I, Salmasi A, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun A, Pantuck A, Chamie K.

Urol Oncol. 2018 Jan;36(1):9.e1-9.e9. doi: 10.1016/j.urolonc.2017.09.001. Epub 2017 Oct 20.

PMID:
29066013
5.

Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma.

Wei X, Choudhury Y, Lim WK, Anema J, Kahnoski RJ, Lane B, Ludlow J, Takahashi M, Kanayama HO, Belldegrun A, Kim HL, Rogers C, Nicol D, Teh BT, Tan MH.

Sci Rep. 2017 Aug 4;7(1):7342. doi: 10.1038/s41598-017-07191-y.

6.

Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.

Lenis AT, Donin NM, Johnson DC, Faiena I, Salmasi A, Drakaki A, Belldegrun A, Pantuck A, Chamie K.

J Urol. 2018 Jan;199(1):43-52. doi: 10.1016/j.juro.2017.04.092. Epub 2017 May 4. Review.

PMID:
28479237
7.

A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer.

Donin NM, Chamie K, Lenis AT, Pantuck AJ, Reddy M, Kivlin D, Holldack J, Pozzi R, Hakim G, Karsh LI, Lamm DL, Belkoff LH, Belldegrun AS, Holden S, Shore N.

Urol Oncol. 2017 Feb;35(2):39.e1-39.e7. doi: 10.1016/j.urolonc.2016.09.006. Epub 2016 Oct 26.

PMID:
28341495
8.

Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility.

Donin NM, Strauss-Ayali D, Agmon-Gerstein Y, Malchi N, Lenis AT, Holden S, Pantuck AJ, Belldegrun AS, Chamie K.

Urol Oncol. 2017 May;35(5):272-278. doi: 10.1016/j.urolonc.2016.11.019. Epub 2017 Jan 3.

PMID:
28065395
9.

Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.

Chamie K, Donin NM, Klöpfer P, Bevan P, Fall B, Wilhelm O, Störkel S, Said J, Gambla M, Hawkins RE, Jankilevich G, Kapoor A, Kopyltsov E, Staehler M, Taari K, Wainstein AJA, Pantuck AJ, Belldegrun AS.

JAMA Oncol. 2017 Jul 1;3(7):913-920. doi: 10.1001/jamaoncol.2016.4419.

10.

Sustained-release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study.

Donin NM, Duarte S, Lenis AT, Caliliw R, Torres C, Smithson A, Strauss-Ayali D, Agmon-Gerstein Y, Malchi N, Said J, Raman SS, Holden S, Pantuck A, Belldegrun AS, Chamie K.

Urology. 2017 Jan;99:270-277. doi: 10.1016/j.urology.2016.09.039. Epub 2016 Oct 5.

PMID:
27720772
11.

Immunotherapy for the Treatment of Urothelial Carcinoma.

Donin NM, Lenis AT, Holden S, Drakaki A, Pantuck A, Belldegrun A, Chamie K.

J Urol. 2017 Jan;197(1):14-22. doi: 10.1016/j.juro.2016.02.3005. Epub 2016 Jul 25. Review.

PMID:
27460757
12.

Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma.

Donin NM, Pantuck A, Klöpfer P, Bevan P, Fall B, Said J, Belldegrun AS, Chamie K.

Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1326-32. doi: 10.1158/1055-9965.EPI-16-0226. Epub 2016 Jul 14.

13.

Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.

Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilgüvar K, Lifton RP, Shuch B.

Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2170-5. doi: 10.1073/pnas.1525735113. Epub 2016 Feb 10.

14.

Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial.

Chamie K, Klöpfer P, Bevan P, Störkel S, Said J, Fall B, Belldegrun AS, Pantuck AJ.

Urol Oncol. 2015 May;33(5):204.e25-33. doi: 10.1016/j.urolonc.2015.02.013. Epub 2015 Mar 29.

PMID:
25823535
15.

Words of wisdom. Re: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Daskivich TJ, Belldegrun A.

Eur Urol. 2015 Apr;67(4):816-7. doi: 10.1016/j.eururo.2014.12.052. No abstract available.

PMID:
25765212
16.

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.

McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB.

Clin Cancer Res. 2015 Feb 1;21(3):561-8. doi: 10.1158/1078-0432.CCR-14-1520. Epub 2014 Nov 25.

17.

The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma.

Hofbauer SL, Pantuck AJ, de Martino M, Lucca I, Haitel A, Shariat SF, Belldegrun AS, Klatte T.

Urol Oncol. 2015 Feb;33(2):68.e1-7. doi: 10.1016/j.urolonc.2014.08.005. Epub 2014 Sep 16.

PMID:
25240758
18.

Nephron-sparing surgery is superior to radical nephrectomy in preserving renal function benefit even when expanding indications beyond the traditional 4-cm cutoff.

Pignot G, Bigot P, Bernhard JC, Bouliere F, Bessede T, Bensalah K, Salomon L, Mottet N, Bellec L, Soulié M, Ferrière JM, Pfister C, Drai J, Colombel M, Villers A, Rigaud J, Bouchot O, Montorsi F, Bertini R, Belldegrun AS, Pantuck AJ, Patard JJ.

Urol Oncol. 2014 Oct;32(7):1024-30. doi: 10.1016/j.urolonc.2014.03.012. Epub 2014 Jul 2.

PMID:
24996775
19.

The contemporary role on surgery in the management of renal masses.

Kroeger N, Belldegrun AS, Pantuck AJ.

World J Urol. 2014 Jun;32(3):571-2. doi: 10.1007/s00345-014-1290-9. No abstract available.

PMID:
24718636
20.

The contemporary role of ablative treatment approaches in the management of renal cell carcinoma (RCC): focus on radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), and cryoablation.

Klatte T, Kroeger N, Zimmermann U, Burchardt M, Belldegrun AS, Pantuck AJ.

World J Urol. 2014 Jun;32(3):597-605. doi: 10.1007/s00345-014-1284-7. Epub 2014 Apr 4. Review.

PMID:
24700308
21.

Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2α.

Kroeger N, Seligson DB, Signoretti S, Yu H, Magyar CE, Huang J, Belldegrun AS, Pantuck AJ.

Eur J Cancer. 2014 May;50(8):1531-40. doi: 10.1016/j.ejca.2014.01.031. Epub 2014 Feb 21.

PMID:
24565854
22.

PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.

Logan JE, Mostofizadeh N, Desai AJ, VON Euw E, Conklin D, Konkankit V, Hamidi H, Eckardt M, Anderson L, Chen HW, Ginther C, Taschereau E, Bui PH, Christensen JG, Belldegrun AS, Slamon DJ, Kabbinavar FF.

Anticancer Res. 2013 Aug;33(8):2997-3004.

PMID:
23898052
23.

Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma.

de Martino M, Pantuck AJ, Hofbauer S, Waldert M, Shariat SF, Belldegrun AS, Klatte T.

J Urol. 2013 Dec;190(6):1999-2004. doi: 10.1016/j.juro.2013.06.082. Epub 2013 Jul 2.

PMID:
23831313
24.

Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience.

Birkhäuser FD, Pantuck AJ, Rampersaud EN, Wang X, Kroeger N, Pouliot F, Zomorodian N, Riss J, Li G, Kabbinavar FF, Belldegrun AS.

Cancer J. 2013 May-Jun;19(3):189-96. doi: 10.1097/PPO.0b013e318292e8a4.

PMID:
23708063
25.

Pomegranate Extracts in the Management of Men's Urologic Health: Scientific Rationale and Preclinical and Clinical Data.

Kroeger N, Belldegrun AS, Pantuck AJ.

Evid Based Complement Alternat Med. 2013;2013:701434. doi: 10.1155/2013/701434. Epub 2013 Mar 26. Erratum in: Evid Based Complement Alternat Med. 2013;2013:870454. N, Kroeger [corrected to Kroeger, Nils]; A S, Belldegrun [corrected to Belldegrun, A S]; A J, Pantuck [corrected to Pantuck, A J].

26.

The effect of gender and age on kidney cancer survival: younger age is an independent prognostic factor in women with renal cell carcinoma.

Rampersaud EN, Klatte T, Bass G, Patard JJ, Bensaleh K, Böhm M, Allhoff EP, Cindolo L, De La Taille A, Mejean A, Soulie M, Bellec L, Christophe Bernhard J, Pfister C, Colombel M, Belldegrun AS, Pantuck AJ, George D.

Urol Oncol. 2014 Jan;32(1):30.e9-13. doi: 10.1016/j.urolonc.2012.10.012. Epub 2013 Feb 17.

PMID:
23422777
27.

Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models.

Birkhäuser FD, Koya RC, Neufeld C, Rampersaud EN, Lu X, Micewicz ED, Chodon T, Atefi M, Kroeger N, Chandramouli GV, Li G, Said JW, McBride WH, Kabbinavar FF, Ribas A, Pantuck AJ, Belldegrun AS, Riss J.

J Immunother. 2013 Feb;36(2):102-11. doi: 10.1097/CJI.0b013e31827bec97.

PMID:
23377663
28.

Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma.

Kroeger N, Klatte T, Chamie K, Rao PN, Birkhäuser FD, Sonn GA, Riss J, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

Cancer. 2013 Apr 15;119(8):1547-54. doi: 10.1002/cncr.27947. Epub 2013 Jan 18.

29.

Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma.

Klatte T, Kroeger N, Rampersaud EN, Birkhäuser FD, Logan JE, Sonn G, Riss J, Rao PN, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

Cancer. 2012 Dec 1;118(23):5777-82. doi: 10.1002/cncr.27607. Epub 2012 May 17.

30.

Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma.

Kroeger N, Seligson DB, Klatte T, Rampersaud EN, Birkhäuser FD, Rao PN, Leppert JT, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

Eur Urol. 2012 May;61(5):888-95. doi: 10.1016/j.eururo.2012.01.012. Epub 2012 Jan 18.

PMID:
22269604
31.

Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma.

Shuch B, Bratslavsky G, Shih J, Vourganti S, Finley D, Castor B, Treat E, Linehan WM, Pantuck AJ, Said JW, Belldegrun AS.

BJU Int. 2012 Jun;109(11):1600-6. doi: 10.1111/j.1464-410X.2011.10785.x. Epub 2012 Jan 5.

32.

Systemic therapy for metastatic renal cell carcinoma: a review and update.

Logan JE, Rampersaud EN, Sonn GA, Chamie K, Belldegrun AS, Pantuck AJ, Slamon DJ, Kabbinavar FF.

Rev Urol. 2012;14(3-4):65-78.

33.

Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation.

Kroeger N, Rampersaud EN, Patard JJ, Klatte T, Birkhäuser FD, Shariat SF, Lang H, Rioux-Leclerq N, Remzi M, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

J Urol. 2012 Feb;187(2):418-23. doi: 10.1016/j.juro.2011.10.024. Epub 2011 Dec 15.

PMID:
22177164
34.

Clear cell renal cell carcinoma: multiphasic multidetector CT imaging features help predict genetic karyotypes.

Sauk SC, Hsu MS, Margolis DJ, Lu DS, Rao NP, Belldegrun AS, Pantuck AJ, Raman SS.

Radiology. 2011 Dec;261(3):854-62. doi: 10.1148/radiol.11101508. Epub 2011 Oct 24.

PMID:
22025734
35.

The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma.

Finley DS, Shuch B, Said JW, Galliano G, Jeffries RA, Afifi AA, Castor B, Magyar C, Sadaat A, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

J Urol. 2011 Dec;186(6):2168-74. doi: 10.1016/j.juro.2011.07.068. Epub 2011 Oct 19.

PMID:
22014797
36.

Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival.

Kroeger N, Klatte T, Birkhäuser FD, Rampersaud EN, Seligson DB, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

Cancer. 2012 Apr 1;118(7):1795-802. doi: 10.1002/cncr.26453. Epub 2011 Aug 25.

37.

Basic research in kidney cancer.

Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H, Belldegrun A.

Eur Urol. 2011 Oct;60(4):622-33. doi: 10.1016/j.eururo.2011.06.048. Epub 2011 Jul 5. Review.

38.

Words of Wisdom. Re: randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.

Rampersaud EN Jr, Belldegrun AS.

Eur Urol. 2011 Feb;59(2):301-2. doi: 10.1016/j.eururo.2010.11.009. No abstract available.

PMID:
21414876
39.

Salvage cryotherapy for radiation-recurrent prostate cancer: outcomes and complications.

Finley DS, Belldegrun AS.

Curr Urol Rep. 2011 Jun;12(3):209-15. doi: 10.1007/s11934-011-0182-4. Review.

40.

Tumor biology and prognostic factors in renal cell carcinoma.

Finley DS, Pantuck AJ, Belldegrun AS.

Oncologist. 2011;16 Suppl 2:4-13. doi: 10.1634/theoncologist.2011-S2-04. Review.

41.

Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling.

Molina A, Belldegrun A.

J Urol. 2011 Mar;185(3):787-94. doi: 10.1016/j.juro.2010.10.042. Epub 2011 Jan 15. Review. Erratum in: J Urol. 2011 Aug;186(2):762.

PMID:
21239012
42.

Ultrasound-based combination therapy: potential in urologic cancer.

Finley DS, Pouliot F, Shuch B, Chin A, Pantuck A, Dekernion JB, Belldegrun AS.

Expert Rev Anticancer Ther. 2011 Jan;11(1):107-13. doi: 10.1586/era.10.174. Review.

PMID:
21166515
43.

Quality of pathological reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance.

Shuch B, Pantuck AJ, Pouliot F, Finley DS, Said JW, Belldegrun AS, Saigal C.

BJU Int. 2011 Aug;108(3):343-8. doi: 10.1111/j.1464-410X.2010.09871.x. Epub 2010 Nov 19.

44.

Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features.

Klatte T, Said JW, Seligson DB, Rao PN, de Martino M, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

J Urol. 2011 Jan;185(1):30-5. doi: 10.1016/j.juro.2010.09.013. Epub 2010 Nov 12.

PMID:
21074210
45.

Immunological therapy in urological malignancy: novel combination strategies.

Finley DS, Pouliot F, Chin AI, Shuch B, Pantuck AJ, Belldegrun AS, Dekernion JB.

Int J Urol. 2011 Feb;18(2):94-101. doi: 10.1111/j.1442-2042.2010.02664.x. Epub 2010 Nov 12. Review.

46.

Contemporary management of renal tumors with venous tumor thrombus.

Pouliot F, Shuch B, Larochelle JC, Pantuck A, Belldegrun AS.

J Urol. 2010 Sep;184(3):833-41; quiz 1235. doi: 10.1016/j.juro.2010.04.071. Review.

PMID:
20643450
47.

Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma.

La Rochelle J, Klatte T, Dastane A, Rao N, Seligson D, Said J, Shuch B, Zomorodian N, Kabbinavar F, Belldegrun A, Pantuck AJ.

Cancer. 2010 Oct 15;116(20):4696-702. doi: 10.1002/cncr.25279.

48.

Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality?

Shuch B, Crispen PL, Leibovich BC, LaRochelle JC, Pouliot F, Pantuck AJ, Liu W, Crepel M, Schuckman A, Rigaud J, Bouchot O, Patard JJ, Skinner D, Belldegrun AS, Blute ML.

BJU Int. 2011 Mar;107(5):724-728. doi: 10.1111/j.1464-410X.2010.09488.x.

49.

Sex, age, and surgeon decision on nephron-sparing surgery are independent predictors of renal masses with benign histologic findings--a multicenter survey.

Zisman A, Patard JJ, Raz O, Klatte T, Haifler M, Mendlovic S, Sandbank J, Belldegrun AS, Lindner A, Leibovici D, Pantuck AJ.

Urology. 2010 Sep;76(3):541-6. doi: 10.1016/j.urology.2010.01.089. Epub 2010 May 21.

PMID:
20494411
50.

Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma.

Klatte T, Remzi M, Zigeuner RE, Mannweiler S, Said JW, Kabbinavar FF, Haitel A, Waldert M, de Martino M, Marberger M, Belldegrun AS, Pantuck AJ.

J Urol. 2010 Jul;184(1):53-8. doi: 10.1016/j.juro.2010.03.026. Epub 2010 May 15.

PMID:
20478577

Supplemental Content

Loading ...
Support Center